分子診断の世界市場予測（～2021年）...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 MARKET SCOPE 20
1.3.1 MARKETS COVERED 20
1.3.2 MOLECULAR DIAGNOSTICS MARKET, BY REGION 21
1.3.3 YEARS CONSIDERED FOR THE STUDY 21
1.4 CURRENCY 21
1.5 STAKEHOLDERS 22

2 RESEARCH METHODOLOGY 23
2.1 MARKET SIZE ESTIMATION 24
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 26
2.2.1 KEY DATA FROM SECONDARY SOURCES 28
2.2.2 KEY DATA FROM PRIMARY SOURCES 29
2.2.2.1 Key industry insights 30
2.2.3 ASSUMPTIONS 30

3 EXECUTIVE SUMMARY 31
3.1 INTRODUCTION 31
3.2 CONCLUSION 35

4 PREMIUM INSIGHTS 36
4.1 MOLECULAR DIAGNOSTICS: MARKET OVERVIEW 36
4.2 MOLECULAR DIAGNOSTICS MARKET SIZE, BY TYPE OF INFECTIOUS DISEASE, 2016 VS. 2021 36
4.3 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY AND APPLICATION 37
4.4 MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2016 VS. 2021 38
4.5 MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT AND SERVICE, 2016 VS. 2021 38
4.6 GEOGRAPHIC GROWTH OPPORTUNITIES: MOLECULAR DIAGNOSTICS MARKET 39

5 MARKET OVERVIEW 40
5.1 INTRODUCTION 41
5.2 MARKET DYNAMICS 41
5.2.1 DRIVERS 42
5.2.1.1 High prevalence of infectious diseases and various types of cancer 42
5.2.1.2 Increasing awareness and acceptance of personalized medicine and companion diagnostics 43
 
5.2.1.3 Growth in the biomarker identification market and advancements in molecular techniques 43
5.2.1.4 Reforms in the reimbursement system in the U.S. 43
5.2.2 RESTRAINTS 44
5.2.2.1 Complex regulatory frameworks to delay approvals of new molecular diagnostic tests 44
5.2.3 OPPORTUNITIES 44
5.2.3.1 Advances in genomics and proteomics 44
5.2.3.2 Increasing adoption of point-of-care testing 45
5.2.3.3 Significant growth prospects in developing countries 45
5.2.4 CHALLENGE 46
5.2.4.1 Dearth of trained professionals limiting the appropriate use of new molecular diagnostic technologies 46

6 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION 47
6.1 INTRODUCTION 48
6.2 INFECTIOUS DISEASES 49
6.2.1 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) 52
6.2.2 HEPATITIS B 53
6.2.3 HUMAN PAPILLOMAVIRUS (HPV) 54
6.2.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 55
6.2.5 TUBERCULOSIS (TB) 56
6.2.6 HEPATITIS C 57
6.2.7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 58
6.2.8 OTHER INFECTIOUS DISEASES 59
6.3 ONCOLOGY 60
6.3.1 BREAST CANCER 63
6.3.2 COLORECTAL CANCER 64
6.3.3 PROSTATE CANCER 64
6.3.4 OTHER CANCERS 65
6.4 BLOOD SCREENING 65
6.5 GENETIC TESTS 68
6.6 MICROBIOLOGY 70
6.7 OTHER APPLICATIONS 74

7 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY 77
7.1 INTRODUCTION 78
7.2 POLYMERASE CHAIN REACTION (PCR) 79
7.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) 81
7.4 HYBRIDIZATION (IN-SITU HYBRIDIZATION & FISH) 84
7.5 DNA SEQUENCING AND NEXT-GENERATION SEQUENCING 87
7.6 MICROARRAY 90
7.7 OTHER TECHNOLOGIES 94

8 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 97
8.1 INTRODUCTION 98
8.2 REAGENTS & KITS 99
8.3 INSTRUMENTS 101
8.4 SOFTWARE & SERVICES 104

9 MOLECULAR DIAGNOSTICS MARKET, BY END USER 107
9.1 INTRODUCTION 108
9.2 HOSPITAL AND ACADEMIC LABORATORIES 109
9.3 REFERENCE LABORATORIES 111
9.4 OTHER END USERS 114

10 MOLECULAR DIAGNOSTICS MARKET, BY REGION 118
10.1 INTRODUCTION 119
10.2 NORTH AMERICA 120
10.2.1 U.S. 124
10.2.2 CANADA 126
10.3 EUROPE 129
10.3.1 GERMANY 133
10.3.2 FRANCE 135
10.3.3 ITALY 137
10.3.4 SPAIN 139
10.3.5 U.K. 141
10.3.6 REST OF EUROPE (ROE) 143
10.4 ASIA-PACIFIC 145
10.4.1 JAPAN 150
10.4.2 CHINA 152
10.4.3 AUSTRALIA 154
10.4.4 INDIA 156
10.4.5 REST OF ASIA-PACIFIC (ROAPAC) 158
10.5 REST OF THE WORLD (ROW) 161
10.5.1 LATIN AMERICA 163
10.5.1.1 Brazil 166
10.5.1.2 Mexico 168
10.5.1.3 Rest of Latin America (RoLA) 170
10.5.2 MIDDLE EAST & AFRICA 172
 

11 COMPETITIVE LANDSCAPE 175
11.1 OVERVIEW 175
11.2 MARKET SHARE ANALYSIS 176
11.3 MOLECULAR DIAGNOSTICS MARKET COMPETITOR SHARE ANALYSIS, BY APPLICATION 177
11.3.1 MARKET SHARE ANALYSIS FOR BLOOD SCREENING APPLICATIONS 177
11.3.2 RANKING FOR MICROBIOLOGY APPLICATIONS 178
11.4 MOLECULAR DIAGNOSTICS MARKET SHARE ANALYSIS, BY TECHNOLOGY 179
11.4.1 POLYMERASE CHAIN REACTION (PCR) 179
11.4.2 DNA SEQUENCING AND NGS 180
11.4.3 MICROARRAY 182
11.4.4 HYBRIDIZATION (IN SITU AND FLUORESCENCE) 183
11.4.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) 183
11.5 NEW PRODUCT LAUNCHES AND APPROVALS 185
11.6 AGREEMENTS, COLLABORATIONS, PARTNERSHIPS, JOINT VENTURES, AND CONTRACTS 186
11.7 ACQUISITIONS 187
11.8 OTHER STRATEGIES 188

12 COMPANY PROFILES 189
(Overview, Products and Services, Financials, Strategy & Development)*
12.1 INTRODUCTION 189
12.2 ABBOTT LABORATORIES 190
12.3 QIAGEN N.V. 194
12.4 ROCHE DIAGNOSTICS 199
12.5 HOLOGIC, INC. 205
12.6 GRIFOLS 209
12.7 SIEMENS HEALTHCARE 212
12.8 BECTON, DICKINSON AND COMPANY 214
12.9 BECKMAN COULTER INC. (A WHOLLY OWNED SUBSIDIARY OF DANAHER CORPORATION) 218
12.10 BIOMÉRIEUX SA 222
12.11 CEPHEID INC. 225
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.
 

13 APPENDIX 228
13.1 INSIGHTS OF INDUSTRY EXPERTS 228
13.2 DISCUSSION GUIDE 229
13.3 OTHER DEVELOPMENTS 231
13.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 235
13.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 237
13.6 AVAILABLE CUSTOMIZATIONS 239
13.7 RELATED REPORTS 240
13.8 AUTHOR DETAILS 241